ADSL and neoplasm: Technological advances in drug delivery, such as nanoparticle-based systems, antibody–drug conjugates, and 3D printing technologies, have further optimized the delivery of AMPs and alkylating agents to tumor sites, improving their bioavailability and therapeutic outcomes.